Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.